What are the early outcomes of percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass grafting (CABG) in patients with two- and three-vessel coronary artery disease?
Nine randomized trails have addressed the relative benefit of PTCA and CABG in patient population of 5,200 patients, including those with two- or three- vessel disease. Individual and combined trial results showed no treatment-related difference in survival, but results of these trials are useful in individualizing the treatment for specific patients with two- or three- vessel coronary artery disease. The largest of these trials was the NIH-sponsored Bypass Angioplasty Revascularization Investigation (BARI), conducted at 18 North American centers with randomization of 1828 patients with two- or three-vessel CAD to receive PTCA or CABG between 1988 and 1991. The table that follows demonstrates that the in-hospital outcome of the two interventional treatments were similar.
Related Questions
- Should percutaneous transluminal angioplasty be recommended for treatment of infrageniculate popliteal artery or tibioperoneal trunk stenosis?
- Can the added risk of stroke from combined coronary artery bypass grafting and carotid endarterectomy be predicted?
- Should patients with stenosis of the left main coronary artery waiting for bypass grafting be given priority?
